<DOC>
	<DOC>NCT00337090</DOC>
	<brief_summary>The study will examine which dose of YM178 is best in terms of efficacy, safety and tolerability compared to placebo and compared to tolterodine, a marketed product.</brief_summary>
	<brief_title>A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Patients over 18 years suffering from overactive bladder (OAB) for more than 3 months Pregnant and breastfeeding women Any medical condition or need for comedication which interferes with the drug under investigation (YM178) or the comparator (tolterodine)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Over Active Bladder</keyword>
	<keyword>Urinary incontinence</keyword>
	<keyword>YM178</keyword>
	<keyword>Symptomatic Over Active Bladder</keyword>
</DOC>